<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    EVELO, Inc.

    EVELO, Inc.

    Evelo develops and sells electric bicycles using a direct-to-consumer distribution...

    Evelo develops and sells electric bicycles usin...

    Amount Raised:    $729,723.00
    Fundraising Status:    VT
    Filing Type:    CF
    Sesen Bio, Inc.

    Sesen Bio, Inc.

    At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...

    At Sesen Bio, we are committed to renewing life...

    Filing Type:    PU
    CHF Solutions, Inc.

    CHF Solutions, Inc.

    CHF Solutions is focused on improving the quality of life for patients suffering f...

    CHF Solutions is focused on improving the quali...

    Filing Type:    PU
    Beyond Air, Inc.

    Beyond Air, Inc.

    Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company d...

    Beyond Air Inc. is a clinical-stage medical dev...

    Filing Type:    PU
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    AdaptHealth Corp.

    AdaptHealth Corp.

    We are a network of full-service medical equipment companies that use tailored pro...

    We are a network of full-service medical equipm...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Tocagen Inc.

    Tocagen Inc.

    Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...

    Tocagen is a clinical-stage, cancer-selective g...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    CohBar, Inc.

    CohBar, Inc.

    CohBar, Inc. is a leader in the research and development of mitochondria based the...

    CohBar, Inc. is a leader in the research and de...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.